Archives of Medical Research
Volume 41, Issue 3 , Pages 182-189 , April 2010

Elevated Serum Level of IL-23 Correlates with Expression of VEGF in Human Colorectal Carcinoma

  • Biljana Ljujic

      Affiliations

    • Center for Molecular Medicine, Faculty of Medicine, University of Kragujevac, Serbia
    • Corresponding Author InformationAddress reprint requests to: Biljana T. Ljujic, MD, Center for Molecular Medicine, Faculty of Medicine, University of Kragujevac, Svetozara Markovica 69, 34 000 Kragujevac, Serbia; Phone: +38134306800; FAX: +38134306800 ext 112
    • ,
  • Gordana Radosavljevic

      Affiliations

    • Center for Molecular Medicine, Faculty of Medicine, University of Kragujevac, Serbia
    • ,
  • Ivan Jovanovic

      Affiliations

    • Center for Molecular Medicine, Faculty of Medicine, University of Kragujevac, Serbia
    • ,
  • Sladjana Pavlovic

      Affiliations

    • Center for Molecular Medicine, Faculty of Medicine, University of Kragujevac, Serbia
    • ,
  • Nemanja Zdravkovic

      Affiliations

    • Center for Molecular Medicine, Faculty of Medicine, University of Kragujevac, Serbia
    • ,
  • Marija Milovanovic

      Affiliations

    • Center for Molecular Medicine, Faculty of Medicine, University of Kragujevac, Serbia
    • ,
  • Ljubisa Acimovic

      Affiliations

    • Center for Molecular Medicine, Faculty of Medicine, University of Kragujevac, Serbia
    • ,
  • Milan Knezevic

      Affiliations

    • Center for Molecular Medicine, Faculty of Medicine, University of Kragujevac, Serbia
    • ,
  • Dragic Bankovic

      Affiliations

    • Faculty of Science, University of Kragujevac, Serbia
    • ,
  • Dusica Zdravkovic

      Affiliations

    • Center for Molecular Medicine, Faculty of Medicine, University of Kragujevac, Serbia
    • ,
  • Nebojsa Arsenijevic

      Affiliations

    • Center for Molecular Medicine, Faculty of Medicine, University of Kragujevac, Serbia

Received 22 October 2009 ,Accepted 29 January 2010.

References 

  1. Colpaert C, Vermulen P, van Beest P, et al. Intratumoural hypoxia resulting in the presence of a fibrotic focus is an independent predictor of early distant relapse in lymph nodenegative breast cancer patients. Histopathology. 2001;39:416–425
  2. Fyles A, Milosevic M, Hedley D, et al. Tumour hypoxia has independent predictor impact only in patients with node negative cervix cancer. J Clin Oncol. 2002;20:680–687
  3. Rajaganeshan R, Prasad R, Guillou PJ, et al. The role of hypoxia in recurrence following resection of Dukes' B colorectal cancer. Int J Colorectal Dis. 2008;23:1049–1055
  4. Wincewicz A, Sulkowska M, Koda M, et al. Clinicopathological significance and linkage of HIF-1 alpha and GLUT-1 distributions in human primary colorectal cancers. Pathol Oncol Res. 2007;13:15–20
  5. Dachs GU, Tozer GM. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer. 2000;36:1649–1660
  6. Ferrara N. VEGF as a therapeutic target in cancer. Oncology. 2005;69(suppl 3):11–16
  7. Mizukami Y, Jo WS, Duerr EM, et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med. 2005;11:992–997
  8. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454:436–444
  9. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867
  10. Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007;133:1099–1105
  11. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451–459
  12. Langrish CL, McKenzie BS, Wilson NJ, et al. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev. 2004;202:96–105
  13. Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006;116:1310–1316
  14. Matsuki T, Nakae S, Sudo K, et al. Abnormal T cell activation caused by the imbalance of the IL-1/IL-1R antagonist system is responsible for the development of experimental autoimmune encephalomyelitis. Int Immunol. 2006;18:399–407
  15. Samoilova EB, Horton JL, Hilliard B, et al. IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. J Immunol. 1998;161:6480–6486
  16. Fantini MC, Pallone F. Cytokines: from gut inflammation to colorectal cancer. Curr Drug Targets. 2008;95:375–380
  17. Wu S, Rhee KJ, Albesiano E, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med. 2009;15:1016–1022
  18. Chen Z, Laurence A, Kanno Y, et al. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci. 2006;103:8137–8142
  19. Alkim C, Savas B, Ensari A, et al. Expression of p53, VEGF, microvessel density, and cyclin-D1 in noncancerous tissue of inflammatory bowel disease. Dig Dis Sci. 2009;54:1979–1984
  20. Giatromanolaki A, Sivridis E, Maltezos E, et al. Hypoxia inducible factor 1α and 2α overexpression in inflammatory bowel disease. J Clin Pathol. 2003;56:209–213
  21. Sulkowski S, Wincewicz A, Zalewski B, et al. Hypoxia related growth factors and p53 in preoperative sera from patients with colorectal cancer–evaluation of the prognostic significance of these agents. Clin Chem Lab Med. 2009;47:1439–1445
  22. Pfannschmidt J, Bade S, Hoheisel J, et al. Identification of immunohistochemical prognostic markers for survival after resection of pulmonary metastases from colorectal carcinoma. Thorac Cardiovasc Surg. 2009;57:403–408
  23. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342
  24. Dassoulas K, Gazouli M, Rizos S, et al. Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival. Mol Carcinog. 2009;486:563–569
  25. Jain L, Vargo CA, Danesi R, et al. The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther. 2009;8:2496–2508
  26. Famulski W, Sulkowska M, Wincewicz A, et al. P53 correlates positively with VEGF in preoperative sera of colorectal cancer patients. Neoplasma. 2006;53:43–48
  27. Díaz R, Peña C, Silva J, et al. p73 isoforms affect VEGF, VEGF165b and PEDF expression in human colorectal tumors: VEGF165b downregulation as a marker of poor prognosis. Int J Cancer. 2008;123:1060–1067
  28. Baltaziak M, Koda M, Wincewicz A, et al. Relationships of p53 and Bak with EPO and EPOR in human colorectal cancer. Anticancer Res. 2009;29:4151–4156
  29. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005;7:211–217
  30. Gordon LI, Weitzman SA. Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood. 1990;76:655–663
  31. Christen S, Hagen TM, Shigenaga MK, et al. Chronic infection and inflammation lead to mutation and cancer. In:  Parsonnet J,  Horning S editor. Microbes and Malignancy: Infection as a Cause of Cancer. New York: Oxford University Press; 1999;p. 35–88
  32. Elson CO, Cong Y, Weaver CT, et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology. 2007;132:2359–2370
  33. Kullberg MC, Jankovic D, Feng CG, et al. IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J Exp Med. 2006;203:2485–2494
  34. Hue S, Ahern P, Buonocore S, et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med. 2006;203:2473–2483
  35. Uhlig HH, McKenzie BS, Hue S, et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity. 2006;25:309–318
  36. Zhang B, Rong G, Wei H, et al. The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun. 2008;26(374):533–537
  37. Stanilov N, Miteva L, Mintchev N, et al. High expression of Foxp3, IL-23p19 and survivin mRNA in colorectal carcinoma. Int J Colorectal Dis. 2009;24:151–157
  38. Schonthaler HB, Huggenberger R, Wculek SK, et al. Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis. Proc Natl Acad Sci. 2009;106:21264–21269
  39. Kortylewski M, Xin H, Kujawski M, et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell. 2009;15:114–123
  40. Lovato P, Brender C, Agnholt J, et al. Constitutive STAT3 activation in intestinal T cells from patients with Crohn's disease. J Biol Chem. 2003;278:16777–16781
  41. Musso A, Dentelli P, Carlino A, et al. Signal transducers and activators of transcription 3 signaling pathway: an essential mediator of inflammatory bowel disease and other forms of intestinal inflammation. Inflamm Bowel Dis. 2005;11:91–98
  42. Corvinus FM, Orth C, Moriggl R, et al. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia. 2005;7:545–555
  43. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001;93:266–276
  44. Xu Q, Briggs J, Park S, et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene. 2005;25(24):5552–5560
  45. Lin J, Jin X, Rothman K, et al. Modulation of signal transducer and activator of transcription 3 activities by p53 tumor suppressor in breast cancer cell. Cancer Res. 2002;62:376–380
  46. Lin J, Tang H, Jin X, et al. p53 regulates Stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active Stat3. Oncogene. 2002;21:3082–3088
  47. Niu G, Wright KL, Ma Y, et al. Role of Stat3 in regulating p53 expression and function. Mol Cell Biol. 2005;25:7432–7440
  48. Semenza GL. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol. 2000;35(71):103
  49. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 2000;14:34–44
  50. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271–275
  51. Fatyol K, Szalay AA. The p14ARF tumor suppressor protein facilitates nucleolar sequestration of hypoxia-inducible factor-1α (HIF-1α) and inhibits HIF-1-mediated transcription. J Biol Chem. 2001;276:28421–28429
  52. Zheng S, Han MY, Xiao ZX, et al. Clinical significance of vascular endothelial growth factor expression and neovascularization in colorectal carcinoma. World J Gastroenterol. 2003;9:1227–1230
  53. Hanrahan V, Currie MJ, Gunningham SP, et al. The angiogenic switch for vascular endothelial growth factor VEGF-A, VEGF-B, VEGF-C and VEGF-D in the adenomacarcinoma sequence during colorectal cancer progression. J Pathol. 2003;200:183–194
  54. Kang SM, Maeda K, Onoda N, et al. Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis. Int J Cancer. 1997;74:502–507
  55. Perrone G, Vincenzib B, Santinib D, et al. Correlation of p53 and bcl-2 expression with vascular endothelial growth factor (VEGF), microvessel density (MVD) and clinicopathological features in colon cancer. Cancer Lett. 2004;208:227–234
  56. Smith DR, Goh HS. p53 and prognosis in colorectal cancer. Ann Acad Med Singapore. 1996;25:107–112
  57. Manne U, Myers RB, Moron C, et al. Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int J Cancer. 1997;74:346–358
  58. Manne U, Weiss HL, Myers RB, et al. Nuclear accumulation of p53 in colorectal adenocarcinoma: prognostic importance differs with race and location of the tumor. Cancer. 1998;83:2456–2467
  59. Katkoori VR, Jia X, Shanmugam C, et al. Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. Clin Cancer Res. 2009;15:2406–2416
  60. Gorgescu CV, Săftoiu A, Georgescu CC, et al. Correlations of proliferation markers, p53 expression and histological findings in colorectal carcinoma. J Gastrointestin Liver Dis. 2007;16:133–139
  61. Zhao DP, Ding XW, Peng JP, et al. Prognostic significance of bcl-2 and p53 expression in colorectal carcinoma. J Zhejiang Univ Sci B. 2005;6:1163–1169

PII: S0188-4409(10)00023-8

doi: 10.1016/j.arcmed.2010.02.009

Archives of Medical Research
Volume 41, Issue 3 , Pages 182-189 , April 2010

Article Tools

* Image Usage & Resolution